BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...
4d
Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with ...
This Phase I dose-escalation study in patients with advanced solid tumors was performed to determine the MTD, overall safety, pharmacokinetic (PK) profile and anti-tumor activity of afatinib ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback